Nabiximols (Sativex), a multiple sclerosis drug made from a combination of TCH and CBD, is approved in the United Kingdom and Canada to treat MS pain. However, researchers think the CBD in the drug may be contributing more with its anti-inflammatory properties than by acting against the pain. Clinical trials of CBD are necessary to determine whether or not it should be used for pain management.
The passing of SB 218 through the Kentucky legislature created a new subsection of KRS 260.850m to 260.289, in which the Industrial Hemp Advisory Board outlines the purpose of an industrial hemp research program, establish license provisions, and create new requirements and license application procedures. This state’s approach is for the potential medical and industrial applications.